La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Reneo Pharmaceuticals Dividende

Dividende contrôle des critères 0/6

Reneo Pharmaceuticals n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	2.0%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$1.69
Prévision de rendement du dividende	0%

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Oct 03

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Apr 25

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Nov 22

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Aug 09

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Apr 22

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

Jan 20

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

Oct 02

Our First Look At Reneo Pharmaceuticals

Aug 15

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de RPHM ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de RPHM ont augmenté.

Rendement des dividendes par rapport au marché

Reneo Pharmaceuticals Rendement des dividendes par rapport au marché

Comment le rendement du dividende de RPHM se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (RPHM)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.4%
Moyenne du secteur (Biotechs)	2.0%
Analyste prévisionnel (RPHM) (jusqu'à 3 ans)	0%

Dividende notable: Impossible d'évaluer le rendement des dividendes de RPHM par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de RPHM par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de RPHM afin de déterminer si ses paiements de dividendes sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car RPHM n'a signalé aucun versement.

Reneo Pharmaceuticals Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell Small Cap Comp Value Index

OnKure, Inc. entered into an agreement to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM)

New major risk - Revenue and earnings growth

Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) for $60.8 million.

Price target decreased by 18% to US$20.98

Reneo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) announces an Equity Buyback for 576,443 shares, for $4.4 million.

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Chief Development Officer notifies of intention to sell stock

New minor risk - Profitability

Price target decreased by 9.1% to US$24.40

Reneo Pharmaceuticals, Inc. announced that it has received $5 million in funding from Abingworth LLP

Reneo Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from Abingworth LLP

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Reneo Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target increased to US$26.83

Founder & Executive Chairman exercised options to buy US$165k worth of stock.

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Reneo Pharmaceuticals, Inc. Appoints Roshawn Blunt to Its Board of Directors

Reneo Pharmaceuticals, Inc. Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study

Reneo Pharmaceuticals, Inc. to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2500 Value Index

Price target decreased to US$24.60

Price target decreased to US$30.00

High number of new directors

Dr. Lon Cardon Not Stands for Re-Election as Member of the Board of Reneo Pharmaceuticals, Inc

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Reneo Pharmaceuticals, Inc. Announces Senior Leadership Promotions

Vineet R. Jindal to Resign as Reneo Pharmaceuticals, Inc.'s Chief Financial Officer, Effective March 31, 2022

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

High number of new directors

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

President recently bought US$64k worth of stock

Our First Look At Reneo Pharmaceuticals

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés